FDA Perspective on Sofosbuvir Therapy for Patients With Chronic Hepatitis C Virus Genotype 1 Infection Who Did Not Respond to Treatment With Pegylated Interferon and Ribavirin-Reference-Cited by-同舟云学术

FDA Perspective on Sofosbuvir Therapy for Patients With Chronic Hepatitis C Virus Genotype 1 Infection Who Did Not Respond to Treatment With Pegylated Interferon and Ribavirin

Published:2014-12 Issue:6 Volume:147 Page:1196-1200
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Mishra Poonam,Florian Jeffry,Qi Karen,Zeng Wen,Naeger Lisa K.,Donaldson Eric,Connelly Sarah,O’Rear Jules,Price Dionne,Murray Jeffrey,Birnkrant Debra

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference13 articles.

1. FDA Presentations at the October 25, 2013, Meeting of the Antiviral Drugs Advisory Committee. Available at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/ucm387736.htm.

2. Interferon responsiveness does not change in treatment-experienced hepatitis C Subjects: implications for drug development and clinical decisions;Liu;Clin Infect Dis,2012

3. Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects;Liu;Hepatology,2013

4. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects;Florian;Hepatology,2013

5. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment;Shiffman;Gastroenterology,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of lipid Nanoparticles in COVID-19 inrepurposing drugs and vaccines;Current Nanoscience;2021-11-17

2. Consenso Mexicano para el Tratamiento de la Hepatitis C;Revista de Gastroenterología de México;2018-07

3. The Mexican consensus on the treatment of hepatitis C;Revista de Gastroenterología de México (English Edition);2018-07

4. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016;Journal of Clinical and Experimental Hepatology;2016-06

5. KASL clinical practice guidelines: management of hepatitis C;Clinical and Molecular Hepatology;2016-03-28